Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.57 |
| ▸ | PYGM | P11217 | 5/20 | 0.56 |
| ▸ | PYGL | P06737 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.55 |
| ▸ | ACLY | P53396 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CCR2 | P41597 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | CCR1 | P32246 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7126595 | 0.83 | CCR2 (0.55) | PYGMPYGLALDH1A1CCR2CCR1 | |
| SCHEMBL7127133 | 0.83 | CCR2 (0.73) | PYGMPYGLCCR2CCR1 | |
| SCHEMBL7118434 | 0.81 | PYGL (0.61) | PYGMPYGLKMT2APTGDR2MEN1 | |
| SCHEMBL7127256 | 0.81 | CCR2 (0.61) | PYGMPYGLPTGDR2ACLYCCR2 | |
| SCHEMBL7126634 | 0.81 | CCR1 (0.60) | PYGLKMT2APTGDR2ACLYMEN1 | |
| SCHEMBL3152930 | 0.77 | KDM4E (0.65) | KDM4ETSHRPTK2BKMT2APTGDR2 | |
| SCHEMBL6431208 | 0.76 | PYGL (0.80) | PYGMPYGLTDP1 | |
| SCHEMBL2897956 | 0.74 | CCR1 (0.60) | PTGDR2ACLYCCR2TDP1CCR1 | |
| SCHEMBL3144199 | 0.74 | CCR2 (0.68) | PTGDR2CCR2CCR1 | |
| SCHEMBL7373349 | 0.74 | KMT2A (0.68) | KDM4ETSHRPTK2BKMT2AACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030186944-A1 | Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics | KRISTIANSEN MARIT (DK) | 2003-10-02 | — | — | US | disclosed |
| US-6590118-B1 | Used in treatment of and/or prevention of diabetes, especially non-insulin dependent diabetes (Type 2 diabetes) | NOVO NORDISK A/S (DK) | 2003-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186944-A1 | Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics | PYGL, GYS2, PYGM | KDM4E 484/4885TSHR 3696/4885PTK2B 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.